Skip to main content
. 2019 Apr 10;12(6):828–835. doi: 10.1016/j.tranon.2019.02.007

Fig. 2.

Fig. 2

Best percentage change in target lesion size from baseline based on RECIST v1.1 per BICR in the full-analysis set. Values ≥100 were set to 100. Data were not available for 13 patients (12.7%). BICR, blinded independent central review; Q3W, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumors.